摘要
达雷妥尤单抗(Daratumumab,Dara)是第一代抗CD38单克隆抗体,具有免疫调节、抗体依赖性细胞介导的细胞毒性作用、抗体依赖性细胞吞噬作用、补体依赖性细胞毒性作用。近年来关于抗CD38单克隆抗体在血液系统疾病中的研究及应用较多,本文旨在综述近年来达雷妥尤单抗在复发难治性多发性骨髓瘤、新诊断的多发性骨髓瘤、系统性淀粉样变性、具有肾脏意义的单克隆丙种球蛋白病等血液系统疾病治疗中的应用及其耐药机制的研究进展。
Daratumumab is the first generation of anti-CD38 monoclonal antibody,which has immunomodulatory,antibody-dependent cell-mediated cytotoxicity,antibody-dependent phagocytosis,and complement-dependent cytotoxicity.In recent years,there have been many studies and applications of anti-CD38 monoclonal antibodies in hematological diseases.The purpose of this review is to review the application of Daratumumab in the treatment of refractory relapsed multiple myeloma,newly diagnosed multiple myeloma,systemic amyloidosis,monoclonal gamma globulinosis with renal significance and the latest research progress in the mechanism of drug resistance.
作者
李转丽
石亚军
白海
LI Zhuanli;SHI Yajun;BAI Hai(The First Clinical Medical College of Gansu University of Chinese Medicine,Gansu Lanzhou 730000,China;The 940th Hospital of Joint Logistic Support Force of PLA,Gansu Lanzhou 730050,China)
出处
《现代肿瘤医学》
CAS
北大核心
2023年第1期192-196,共5页
Journal of Modern Oncology
基金
甘肃省科技重大专项计划项目(编号:1102FKDA005)。
